Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
20 hedge funds and large institutions have $3.19M invested in Timber Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
9% less funds holding
Funds holding: 22 → 20 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less capital invested
Capital invested by funds: $6.44M → $3.19M (-$3.25M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$194K |
| 2 |
Renaissance Technologies
New York
|
+$87.7K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$80.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$28.4K |
| 5 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
+$2.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$815K |
| 2 |
Barclays
London,
United Kingdom
|
-$115K |
| 3 |
Millennium Management
New York
|
-$64K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$57K |
| 5 |
Goldman Sachs
New York
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$1K | – | – |
|
TMBR Hedge Fund Activity: Q4 2018 in Review
20 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2018, worth a combined $3.19M — down 50% from $6.44M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TMBR and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $194K. The largest seller was Franklin Resources, cutting an estimated $815K.
- 20 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2018, down from 22 in Q3 2018.
- Funds reported $3.19M of Timber Pharmaceuticals, Inc. stock for Q4 2018, down 50% quarter-over-quarter.
- 1 fund opened new Timber Pharmaceuticals, Inc. positions in Q4 2018 and 3 closed out, a net change of -2 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q4 2018 was Vanguard Group, an estimated $194K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2018 was Franklin Resources, an estimated $815K sold.
Based on aggregated 13F filings for Q4 2018.